{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-364991","form_type":"8-K","ticker":"ZLAB","cik":"0001704292","company_name":"Zai Lab Ltd","filed_at":"2021-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.752455+00:00","generated_at":"2026-06-27T23:00:22.160877+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zai Lab promotes Harald Reinhart to President and Head of Global Development","bullets":["Harald Reinhart, M.D., promoted from CMO to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases","Reinhart received a special equity grant of 30,000 restricted share units, with 50% vesting immediately and 50% on Dec 31, 2022","Base salary and target bonus for 2022 and 2021 bonus increased to be commensurate with other executive officers","Reinhart has been with Zai Lab since inception, first as advisor and since 2017 as CMO","Prior to Zai Lab, he served at Shionogi U.S., Novartis, and Bayer Corp with broad clinical development experience"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-364991","json":"https://secwatch.observer/filing/0001193125-21-364991.json","markdown":"https://secwatch.observer/filing/0001193125-21-364991.md","text":"https://secwatch.observer/filing/0001193125-21-364991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/0001193125-21-364991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/d278574d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:00:22.160877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21f118875c","claim":"Harald Reinhart changed role as President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.","evidence_excerpt":"On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704292/000119312521364991/0001193125-21-364991-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}